

IRA e-bulletin

Newsletter For Health Professionals in Rheumatology

From the Editor's Desk



Latest Research



Expert Opinion



Conference Calendar



IRA Matters



News from EULAR 2013



Do You Know?





Latest Research

Seventeen percent of the RA patients smoked in 2010 in this large Swedish RA cohort. Stopping smoking after onset of RA did not change the poor prognosis of smokers with RA.

The Effect of Stopping Smoking on Disease Activity in Rheumatoid Arthritis (RA). Data from BARFOT, a Multicenter Study of Early RA.

Andersson ML, et al. Open Rheumatol J. 2012;6:303-309.

Read More →

Triple Therapy is as good as biologics in the treatment of rheumatoid arthritis. The RACAT (Rheumatoid Arthritis: Comparison of Active Therapies) trial, a multicenter, 48-week, randomized study with 353 rheumatoid arthritis patients.

Therapies for Active Rheumatoid Arthritis after Methotrexate Failure O'Dell JR, et al. N Engl J Med. 2013 Jun 11. [Epub ahead of print]

Read More →

7 Retreatment of RA patients who were responders to an initial course

of rituximab provided similar clinical outcomes regardless of whether the follow-up course entailed a single 1-g infusion or the approved

two 1-g infusions given 2 weeks apart.

Evaluation of Low-Dose Rituximab for the Retreatment of Patients with Active Rheumatoid Arthritis: A Non-inferiority Randomised Controlled Trial.

Mariette X, et al. Ann Rheum Dis. 2013 May 30. [Epub ahead of print]

Read More →

Tocilizumab monotherapy was superior to adalimumab monotherapy for the reduction of signs and symptoms of RA patients for whom methotrexate was deemed inappropriate.

Tocilizumab Monotherapy versus Adalimumab Monotherapy for Treatment of Rheumatoid Arthritis (ADACTA): A Randomised, Double-blind, Controlled Phase 4 Trial.

Gabay C, et al. Lancet. 2013;381(9877):1541-1550.

Read More →